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OBJECTIVE — Type 2 diabetes is associated with left ventricular hypertrophy (LVH) and
diastolicdysfunction,whichmayeventuallyleadtoclinicalheartfailure.Wesoughttodetermine
the cardiovascular effects of adolescent-onset type 2 diabetes.
RESEARCH DESIGN AND METHODS — We recruited diabetic girls (8 with type 2
and11withtype1diabetes)fromahospitaldiabetesserviceandnondiabeticcontrolsubjects(9
lean and 11 overweight) from the schools of the diabetic subjects. Echocardiography and mea-
surements were performed by a single observer, blinded to subject group allocation, and in-
cluded M-mode left ventricular dimensions, two-dimensional left ventricular mass, Doppler
diastolic ﬂows, estimation of left ventricular ﬁlling pressure, and systolic longitudinal motion.
Leftventricularmasswasindexedtoheightandfat-freebodymass.ANOVAwasusedtocompare
the groups.
RESULTS — The groups were similar in age and height, but signiﬁcant differences in body
composition were observed. Subjects with type 2 diabetes had larger left ventricular dimensions
andleftventricularmass,whichpersistedwhenindexedtoheight.Diastolicﬁllingwasimpaired
inbothdiabeticgroups,andsystoliclongitudinalfunctionwaslowerinthetype2diabeticgroup.
Half of the group with type 2 diabetes met the published criteria for LVH and left ventricular
dilatation; 25% had evidence of elevated left ventricular ﬁlling pressure in association with
structural abnormalities.
CONCLUSIONS — This study has demonstrated preclinical abnormalities of cardiac struc-
ture and function in adolescent girls with type 2 diabetes, despite the short duration of diabetes
and highlights the potential high cardiovascular risk occurring in adolescent type 2 diabetes.
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dolescent-onset type 2 diabetes is
an increasingly prevalent condition
occurring in response to childhood
obesity (1) and is associated with dyslip-
idemia, hypertension, and microalbu-
minuria, all with greater prevalence and
rapid progression than in similarly aged
patients with type 1 diabetes (2). The
main cause of death in adults with type 2
diabetes is cardiovascular disease, irre-
spective of age at diagnosis (3,4). No data
exist regarding the cardiovascular prog-
nosisofadolescent-onsettype2diabetes,
but early-onset type 2 diabetes has been
linked to premature clinical atheroscle-
rosis (5).
Adult-onset type 2 diabetes is asso-
ciated with cardiovascular risk factors,
including obesity, hypertension, dys-
lipidemia, and coronary heart disease
butisalsoassociatedwithdeleteriouscar-
diac changes that may lead to clinical
heartfailure(6),includingleftventricular
hypertrophy (LVH) (7) and diastolic dys-
function (8). Furthermore, obesity is as-
sociated with LVH and diastolic and
systolic dysfunction (9), all of which may
be reversible with weight loss (10). In
children,obesityhasbeenassociatedwith
cardiacenlargement(LVHanddilatation)
(11) and some measures of diastolic dys-
function (12).
The direct cardiac effects of adoles-
cent type 2 diabetes have not been de-
scribed previously. Thus, the aim of this
study was to determine whether cardiac
structural and functional abnormalities
occurinadolescent-onsettype2diabetes.
We hypothesize that the obesity-related
cardiovascular changes may be further
augmented when obese adolescents de-
velop type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Forty adolescent girls
(aged12–18years)withdiabetes(20with
type 1 diabetes and 20 with type 2 diabe-
tes) were identiﬁed from our hospital ad-
olescent diabetes database and invited to
participate: 11 patients with type 1 and 8
patients with type 2 diabetes agreed to
participate. Twenty healthy, nondiabetic
girls were recruited from the schools of
the diabetic participants and formed
two control subject groups: lean and
overweight/obese based on age- and
sex-speciﬁc BMI equivalents (13). No
participants had diabetes complications,
coexisting cardiovascular disease, or a
historyofdiabeticketoacidosisinthepast
12 months. Participants with type 2 dia-
betes were not receiving insulin therapy:
in all patients, diabetes was treated either
by diet alone and/or by metformin. All
nondiabetic participants had A1C levels
6%andfastingglucose5.5mmoland
were pubertal stage 4 or 5 and postmen-
archal. All participants had reported low
physical ﬁtness (3 h/week of moderate/
intense physical activity). This study was
approved by the Auckland Northern Re-
gional Ethics Committee, and all partici-
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participating; those aged 16 years re-
quired parental consent to participate in
the study. A fasting venous blood sample
was collected for determination of A1C
and fasting blood glucose (FBG). During
the same visit, body composition and
echocardiography were performed.
Measurements of body size and body
composition
Height and weight were measured. Body
surface area (BSA) was calculated using
the DuBois formula; BMI was calculated
as weight in kilograms divided by the
square of height in meters. Dual-photon
X-ray absorptiometry (GE Lunar Prodigy;
GE Healthcare, Madison, WI) was per-
formed to determine body composition
including fat-free mass (FFM), fat mass,
bone mineral content, and total weight
using standard analytical software.
Echocardiography
Allimagesweredigitallyacquired(Philips
iE33 or Philips HDI-5000; Phillips Medi-
cal Systems, Bothell, WA) according to a
standardizedprotocolbytrainedresearch
sonographers and measured off-line (Di-
giView;Digisonics,Houston,TX)without
knowledge of the patients’ clinical details
or group allocation. A comprehensive re-
search echocardiogram was performed,
including standard transthoracic views,
aswellasprotocol-speciﬁcmeasurements
(below).
Two-dimensional left ventricular
mass
Images were obtained in the parasternal
short-axis view at the midpapillary mus-
cle level and left ventricular mass was cal-
culated using the area-length method
recommendedbytheAmericanSocietyof
Echocardiography (14). Left ventricular
mass was indexed to height and FFM.
Pulsed-wave Doppler and tissue
Doppler
Mitral valve inﬂow pulsed-wave Doppler
recordings were made between the leaﬂet
tips, isovolumic relaxation time (IVRT)
recordings were made from the left ven-
tricular outﬂow tract, and tissue Doppler
imaging recordings were obtained from
themedialandlateralaspectsofthemitral
annulus in the apical four-chamber view.
All Doppler signals were acquired using a
5-mm sample volume, optimized, and re-
corded at 100 mm/s sweep speed.
Measurements
Measurements were the following: 1)M -
mode measurements: left ventricular end-
diastolic dimension and left ventricular
end-systolic dimension; 2) two-dimen-
sional images: left atrial area; 3) Doppler
measurements: mitral valve early ﬁlling ve-
locity (E), late-ﬁlling velocity (A), mitral E
wave deceleration time, and IVRT, and 4)
tissue Doppler measurements (average of
lateral and medial): mitral annular E veloc-
ity (Ea), mitral annular A velocity (Aa), and
mitralannularSvelocity(Sa).Thefollowing
variables were calculated: E-to-A ratio, left
ventricularejectionfraction,andE-to-Eara-
tio (average).
Statistical analysis
Comparisons between groups for contin-
uous normally distributed variables were
performed using Student’s t test or
ANOVA for more than two groups.
Tukey’sposthoctestwasappliedtoassess
pairwise differences within the ANOVA.
Nonparametric continuous data were ana-
lyzed using Wilcoxon and Kruskall-Wallis
tests, where appropriate. Differences be-
tween categorical variables were assessed
using 
2analysis. P0.05 was accepted as
indicating signiﬁcance.
RESULTS— Thirty-nine girls com-
pleted all assessments: 11 with type 1 di-
abetes, 8 with type 2 diabetes, 9 lean
control subjects, and 11 overweight/
obese control subjects. Age and height
were similar, but signiﬁcant differences
were seen across the groups in weight,
BSA, BMI, and percent body fat (Table 1).
Weight,BSA,andBMIwerehighestinthe
type 2 diabetic group. No signiﬁcant dif-
ferences in body size were observed be-
tween the type 1 diabetic group and lean
control subjects. Percent body fat was
highest in the type 2 diabetic group and
the overweight control subjects but not
different between them. Although the
type 1 diabetic group exhibited signiﬁ-
cantlylowerpercentbodyfat,itremained
higher than that for the lean control sub-
jects (P  0.05). Duration of diabetes was
longer in the type 1 diabetic group (P 
0.004). Both FBG and A1C were signiﬁ-
cantlyelevatedinthetwodiabeticgroups,
withsigniﬁcantlyhigherFBGinthetype1
diabetic group (P  0.05), but no differ-
ence in A1C was seen between the two
diabetic groups nor were any echocardio-
graphic measures correlated with A1C.
Cardiac structure
The type 2 diabetic group had the largest
hearts (left ventricular diameter, left ven-
tricular mass, and LA area) (Table 2). The
largest left ventricular diameters were ob-
served in the type 2 diabetic group: sig-
niﬁcant differences in end-diastolic left
Table 1—Baseline demographics and body composition of the four groups
Type 1
diabetes
Type 2
diabetes
Lean control
subjects
Overweight control
subjects ANOVA P value
n 11 8 9 11
Age (years) 15.5  1.1 14.9  1.1 14.9  1.182 15.3  1.51 0.62
Height (m) 1.63  0.06 1.67  0.08 1.67  0.07 1.61  0.05 0.13
Weight (kg) 65.0  9.89 107.2  24.06 58.1  7.87 80.6  16.26 0.0001
BSA (cm
2) 1.69  0.13 2.13  0.24 1.65  0.13 1.84  0.18 0.0001
Body fat (%) 35.9  7.8 43.9  5.8 28.1  5.7 43.0  3.6 0.0001
BMI (kg/m
2) 24.5  3.6 38.3  7.4 20.8  2.0 30.9  5.3 0.0001
FFM (kg) 42.0  4.4 57.4  8.1 42.3  5.1 46.8  9.4 0.0003
Duration of diabetes (months) 66 (13–128) 20 (6–36) — —
Fasting blood glucose (mmol/l) 15.2  6.3 9.4  5.2 4.5  0.34 4.9  0.52 0.0001
A1C (%) 8.7  1.0 8.2  2.1 5.1  0.21 5.1  0.32 0.0001
Values are means  SD or median (interquartile range).
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tweenthetype2diabeticgroupsandboth
the type 1 diabetic group and the lean
control subjects (both P  0.05). These
differences remained when indexed to
height. Left atrial size was also higher in
the type 2 diabetic group and overweight
control subjects. The highest left ventric-
ular mass occurred in the type 2 diabetic
group (P  0.001); this was signiﬁcantly
different from that in both the lean con-
trol subjects and type 1 diabetic group
(both P  0.05) but similar to that in the
overweight control subjects. These rela-
tionships persisted when left ventricular
mass was indexed to height (P  0.02)
but not when left ventricular mass was
indexed to FFM (P  0.54) (Fig. 1).
Cardiac function
The type 2 diabetic group demonstrated
differences in diastolic ﬁlling and systolic
function. Speciﬁcally, there was a decline
intheE-to-Aratioacrossthegroups,with
dominant late ﬁlling in both diabetic
groups, a pattern of diastolic ﬁlling usu-
allyseeninolderindividuals.Thisdecline
was driven primarily by signiﬁcant differ-
Table 2—Echocardiographic measurements of heart size
Type 1
diabetes
Type 2
diabetes
Lean control
subjects
Overweight control
subjects ANOVA P value
n 11 8 9 11
Echocardiographic structural measurements
LVEDD (cm) 4.71  0.43 5.42  0.36 4.85  0.49 5.08  0.37 0.006
LVEDD/height (cm/m) 2.89  0.26 3.24  0.23 2.91  0.23 3.15  0.23 0.006
LVESD (cm) 2.87  0.38 3.50  0.42 3.03  0.45 3.13  0.37 0.015
LVESD/height (cm/m) 1.76  0.23 2.09  0.27 1.81  0.24 1.94  0.21 0.021
LV mass (g) 116.8  15.6 170.3  32.9 116.1  33.8 137.2  12.6 0.001
LV mass/height (g/m) 71.6  8.7 102.1  21.0 69.2  17.2 84.9  18.7 0.0007
LV mass/FFM (g/kg) 2.78  0.27 2.97  0.56 2.71  0.48 2.93  0.0.41 0.54
Ejection fraction (%) 69.0  6.8 64.2  5.9 67.4  5.9 68.0  5.5 0.38
Left atrial area (cm
2) 17.1  2.2 19.3  1.5 16.5  2.4 18.5  2.8 0.067
Left atrial area/height (cm
2/m) 10.5  1.2 11.6  1.2 9.9  1.4 11.5  1.8 0.047
Echocardiographic functional measurements
E velocity (cm/s) 94.5  13.6 100.5  18.4 92.8  11.7 92.7  12.4 0.63
A velocity (cm/s) 60.8  12.6 56.4  12.8 38.1  7.1 45.7  11.4 0.0003
E-to-A ratio 1.61  0.32 1.86  0.45 2.52  0.54 2.21  0.78 0.005
IVRT (ms) 50.3  8.1 50.9  10.1 43.4  6.5 54.9  9.0 0.04
Average Ea (cm/s) 16.04  2.4 12.6  3.5 16.0  1.40 16.2  4.0 0.057
Average E-to-Ea ratio 6.1  1.3 8.4  2.4 5.8  0.9 6.0  1.6 0.005
Average Sa (cm/s) 10.5  2.5 7.2  2.5 9.1  1.2 8.4  1.1 0.008
Proportion with abnormalities
LV dilatation (referent) 0 5 (63) 1 (11) 3 (27)
Elevated LV mass (referent) 0 6 (75) 1 (11) 4 (36)
LA dilatation (referent) 1 (9) 3 (38) 0 3 (27)
E-to-Ea ratio 9 cm/s (referent) 0 4 (50) 0 1 (9)
E-to-Ea ratio 12 cm/s (referent) 0 2 (25) 0 0
No abnormality 10 (91) 1 (12) 8 (89) 5 (45)
One abnormality 1 (9) 1 (12) 0 5 (45)
Two abnormalities 0 3 (38) 1 (11) 0
Three abnormalities 0 1 (12) 0 1 (9)
Four abnormalities 0 2 (25) 0 0
Values are means  SD or n (%). LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension.
Figure 1—Left ventricular (LV) mass by group: LV mass (A), LV mass/height (B), and LV mass/FFM (C).T1DM, type 1 diabetes; T2DM, type 2
diabetes.
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ble 2). These abnormalities in diastolic
function were conﬁrmed by prolonged
isovolumic relaxation in all groups, ex-
cept the lean control subjects (P  0.04),
and a trend toward reduced left ventricu-
lar longitudinal relaxation (Ea velocity),
(P  0.057). Left ventricular ﬁlling pres-
sure (estimated from the E-to-Ea ratio)
wasdifferentacrossthegroups:itwassig-
niﬁcantly higher in the type 2 diabetic
group (all P  0.05).
Longitudinal left ventricular systolic
function (measured by longitudinal an-
nular motion [Sa]) was lowest in the type
2 diabetic group, different across the
groups, and different between the two di-
abetic groups (P  0.05). In summary,
tissue Doppler velocities indicated lower
diastolic and systolic longitudinal myo-
cardial motion and higher left ventricular
ﬁlling pressure in the type 2 diabetic
group (Fig. 2).
Detection of abnormal echo
measurements
Compared with published normal values
for adult women (14), 63% of the type 2
diabeticgroupmetthecriteriaforleftven-
tricular dilatation, compared with 11% of
the lean control subjects and 27% of the
overweight control subjects (Table 2);
75% met the published criteria for LVH,
compared with 11% of the lean control
subjects and 36% of the overweight con-
trol subjects; 38% had larger left atrial ar-
eas, compared with 9% of the type 1
diabeticgroupand27%oftheoverweight
control subjects; and 50% fell outside the
range of normal left ventricular ﬁlling
pressure (E-to-Ea ratio 9 cm/s) (15), of
whom three of four subjects had dilated
left ventricles and dilated left atria and
metthecriteriaforLVH.Importantly,just
one type 2 diabetic subject had no abnor-
malities detected and one subject had a
single abnormality present. The remain-
der had two or more abnormalities de-
tected. Half of the overweight control
subjects had a single abnormality de-
tected, and in all subjects this was LVH.
Nearly all of the type 1 diabetic and lean
control subjects had no abnormalities
detected.
CONCLUSIONS— This study is the
ﬁrst to demonstrate that important car-
diac abnormalities occur early in adoles-
cent-onset type 2 diabetes and highlights
the potential for higher cardiovascular
risk. By comparing type 2 diabetic girls
with age-matched girls with type 1 dia-
betes and lean and overweight control
subjects, we found that obesity was asso-
ciated with increased cardiac dimensions
and higher left ventricular mass, both of
which were further augmented by the
addition of type 2 diabetes. Further-
more, in the type 2 diabetic group there
was evidence of impaired diastolic and
systolic function, increased left ventric-
ularﬁllingpressure,andlargerleftatrial
volume, a marker of long-standing dia-
stolic disease.
Adolescent-onset type 2 diabetes is a
disturbing worldwide epidemic (2). Usu-
ally a disease of older patients, type 2 di-
abetes often coexists with multiple other
cardiovascular risk factors, including hy-
perlipidemia, hypertension, and obesity
and is associated with poor cardiovascu-
lar outcome (3). LVH, one of the ﬁrst
signs of diabetic cardiomyopathy, may
eventuallyprogresstoleftventriculardys-
function and clinical heart failure (16)
and is an independent risk factor for car-
diovascularmorbidityandmortality(17).
Hypertrophy of cardiac myocytes occurs
in response to increased load, leading to
increased left ventricular wall thickness
and mass. Adolescent obesity has been
previously associated with increased left
ventricular volumes and mass (11), but
obesity is also associated with diastolic
dysfunction (18) and may independently
lead to heart failure (19).
Although left ventricular mass was
similar between the type 2 diabetic group
and the overweight control subjects and
different from that of the lean and type 1
diabetic control groups, left ventricular
dilatation and functional differences were
only seen in the type 2 diabetic group,
suggesting that obesity may be an impor-
tant factor contributing to structural
changesintheheartandthatthepresence
of diabetes augments these changes. The
overweight control subjects in our study
displayedimportantleftventricularstruc-
tural changes, comparable with those of
the type 2 diabetic subjects: both had
higher left ventricular mass and this re-
mained true when left ventricular mass
was indexed to height. Because left ven-
tricular mass is related to body composi-
tion, in particular FFM (20), the higher
left ventricular mass in these groups
mightsimplyreﬂectnormalphysiological
growth in response to higher FFM. Al-
though FFM may be the ideal indexing
variable for left ventricular mass (20), few
data exist regarding the relationship be-
tween FFM and LVH in overweight and
obese subjects. Indeed, when left ventric-
ular mass was indexed to FFM, no differ-
ences were detected among the groups in
our study. However, the functional
changes observed in the type 2 diabetic
groupsuggestthatthehigherLVmassob-
served may be abnormal.
Elevated left ventricular mass leads to
alterations in both myocardial relaxation
and passive ﬁlling of the left ventricle
(16), and adults with type 2 diabetes ex-
hibit a high prevalence of diastolic dys-
function (8) as do patients with type 1
diabetes (21). In the current study, a de-
pendence upon active rather than passive
diastolic ﬁlling was observed in both dia-
betic groups, despite the shorter duration
of diabetes in the type 2 diabetic group.
Figure 2—Pulsed-wave tissue Doppler velocities. Average Ea velocity (A), average Sa (B), and average E:Ea (C). T1DM, type 1 diabetes; T2DM,
type 2 diabetes; TDI, tissue Doppler imaging.
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diabetic participants reﬂects a longer expo-
suretoobesityandothercardiovascularrisk
factors rather than diabetes per se. Obesity
is related to hypertension as well as to dia-
betes,anditisdifﬁculttomeasureexposure
to either in retrospect, perhaps explaining
the lack of association between duration of
diabetes and cardiac adaptation.
Thisistheﬁrststudytodocumentthe
direct structural and functional effects of
type 2 diabetes on the heart. Obesity in
adolescents and young adults has been
linked with hypertension (22) and car-
diovascular disease (23) in later life and
there are some data about the direct car-
diovasculareffectsofobesity:inastudyof
young women (mean age 30 years), obe-
sity (average duration 12 years) was asso-
ciated with higher left ventricular mass
and diastolic and systolic abnormalities
similartothoseseeninthetype2diabetic
group in the current study (12). Our sub-
jects were younger with shorter exposure
to obesity and yet displayed comparable
structural and functional changes.
Adolescent-onset type 2 diabetes is a
relatively new disease and increasingly
prevalent; thus, long-term data are lim-
ited and the prognostic implications of
the abnormalities detected in this study
are unknown. However, many of these
parameters predict cardiovascular out-
come in other population cohorts, and
these adverse changes may be the precur-
sor of future cardiovascular disease and
are unlikely to reverse without signiﬁcant
intervention. In fact, these adolescents
mayalreadybeprogressingtowarddevel-
opment of the clinical syndrome of heart
failure. Recent American College of Car-
diology/AmericanHeartAssociationheart
failure guidelines (24) describe heart fail-
ure as a continuum that begins with risk
factors, including diabetes and hyperten-
sion (stage A), followed by the develop-
ment of structural heart disease (stage B)
and eventually leading to the clinical syn-
drome of heart failure (stages C and D).
Becausethediagnosisoftype2diabetesis
a recognized contributor to stage A heart
failure, the additional ﬁndings of struc-
tural and functional abnormalities (LVH
and diastolic and systolic dysfunction)
suggest that some of these girls could and
shouldbeconsideredtohavestageBheart
failure already.
LVH is an important and modiﬁable
cardiovascular risk factor. Substantial
data exist to support the use of antihyper-
tensivetherapy(especiallyACEinhibitors
and angiotensin receptor blockers) for
lowering blood pressure and regressing
LVH, but many therapies are not regis-
tered for use nor proven in children. Sig-
niﬁcant weight reduction, such as might
be achieved through bariatric surgery or se-
verecaloricrestriction,mayresultinregres-
sion of left ventricular mass and reversal of
functional (10) and cardiovascular changes
(23). Furthermore, physical exercise is rec-
ommendedbytheAmericanDiabetesAsso-
ciation to delay the onset of cardiovascular
disease in type 2 diabetes. Thus, a strategy
to promote exercise and sustain weight loss
may reverse this premature myocardial
aging.
Limitations
We found large and clinically signiﬁcant
differences among the groups and a high
proportion of subjects with echocardio-
graphic measurements that fell outside of
the normal range using adult female nor-
mal values. We used adult normal values
to ensure that we did not overdiagnose
abnormalitiesbyusingadolescentnormal
ranges. If anything, the use of adolescent
normal values would have increased the
number of subjects with abnormal echo-
cardiographic measurements of left ven-
tricular size and hypertrophy. The
diabetic subjects in this study were not
matched for duration of diabetes, nor was
it possible to match them by A1C, al-
though both groups had elevated A1C. It
ispossiblethattheabnormalitiesdetected
in this study may be related to both dis-
ease duration and glycemic control, as
well as to other cardiovascular risk fac-
tors; however, it was not possible to de-
terminepredictorsoftheseabnormalities.
The results of this small study require
conﬁrmation in larger cohorts with longi-
tudinal data to determine whether these
abnormalities progress.
In summary, to our knowledge this is
the ﬁrst study to report potentially impor-
tant left ventricular structural and func-
tional changes associated with adolescent-
onset type 2 diabetes. Compared with
age-matched control subjects, girls with
type 2 diabetes exhibited signiﬁcant LVH
and a high prevalence of abnormal echo-
cardiographic measurements. If left un-
checked,itislikelythatthesechangeswill
leadtothedevelopmentofclinicallyovert
cardiovascular disease.
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